BIO demands withdrawal of 'draconian' IPI proposals
US President Donald Trump's administration has been criticized for continuing to defend 'flawed' proposals for changing the way that Medicare drug prices are set.
Mr Trump and Alex Azar, Secretary for Health and Human Services, announced plans for the new Medicare Part B model using the international pricing index (IPI) in October, saying that they would cut down on “foreign freeloading” and reduce US drug prices.
The Biotechnology Innovation Organization (BIO), the lobbying group for the US biotech industry, was among those to express concerns about the plans at the time, and it has accused the administration of defending them with rhetoric that is as 'flawed' as the plans themselves.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze